Sumitomo Pharma America, Inc.
This is an open label, multi-center, Phase 1/2 study of BBI608 administered in combination with immunotherapy in adult patients with advanced cancers. The goal of the study is to determine the RP2D of BBI608 in combination with each of the immunotherapeutic agents.
Cancer
BBI608
Ipilimumab
Nivolumab
Pembrolizumab
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 104 participants |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase Ib/II Clinical Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors to Adult Patients With Advanced Cancers |
Actual Study Start Date : | August 2015 |
Estimated Primary Completion Date : | January 29, 2021 |
Estimated Study Completion Date : | January 29, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: Combo with Ipilimumab |
Drug: BBI608 Drug: Ipilimumab |
Experimental: Combo with Nivolumab |
Drug: BBI608 Drug: Nivolumab |
Experimental: Combo with Pembrolizumab |
Drug: BBI608 Drug: Pembrolizumab |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
University of Colorado Cancer Center
Denver, Colorado, United States, 80045
Not yet recruiting
Emory University Winship Cancer Institute
Atlanta, Georgia, United States, 30322
Not yet recruiting
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States, 60637
Not yet recruiting
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States, 02114
Not yet recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Not yet recruiting
Weill Cornell Medical College
New York, New York, United States, 10065
Not yet recruiting
Institute for Translational Oncology Research
Greenville, South Carolina, United States, 29605
Not yet recruiting
MD Anderson Cancer Center
Houston, Texas, United States, 77030